Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 909 in its research report dated September 06, 2018.
Prabhudas Lilladher's research report on Aurobindo Pharma
ARBP has acquired a selected group of products of Sandoz in derma, CNS, women healthcare and hormonal drugs in US. The net addition of sales and EBITDA post acquisition is likely to be US$900m and US$180m, respectively. With all-cash deal of US$900m, the acquisition is valued at 1x P/Sales and 5x EV/EBITDA, which is cheapest generic acquisition in US in recent times. With linkage to captive API, diversification of US portfolio and de-risking of manufacturing activities, we expect the acquisition to be EPS accretive from the first year of integration which is likely to be in FY20E.
We maintain 'Buy' and retain TP at Rs909 (18xFY20 EPS).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.